Wells Fargo & Company Moleculin Biotech, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.41 - $0.86 $200 - $419	-488 Reduced 68.06%	229 $0
Q3 2023 Nov 13, 2023	BUY	$0.38 - $0.72 $191 - $362	503 Added 235.05%	717 $0
Q2 2023 Aug 15, 2023	BUY	$0.54 - $0.95 $8 - $15	16 Added 8.08%	214 $0
Q1 2023 May 12, 2023	SELL	$0.9 - $1.34 $289 - $431	-322 Reduced 61.92%	198 $0
Q4 2022 Feb 13, 2023	BUY	$0.85 - $16.65 $280 - $5,494	330 Added 173.68%	520 $0
Q3 2022 Nov 14, 2022	SELL	$1.15 - $17.4 $1 - $17	-1 Reduced 0.52%	190 $0
Q2 2022 Aug 12, 2022	SELL	$1.19 - $2.0 $4,742 - $7,970	-3,985 Reduced 95.43%	191 $0
Q1 2022 May 16, 2022	BUY	$1.23 - $1.9 $1 - $1	1 Added 0.02%	4,176 $7,000
Q4 2021 Feb 14, 2022	BUY	$1.64 - $2.83 $6,560 - $11,320	4,000 Added 2285.71%	4,175 $7,000
Q3 2021 Nov 15, 2021	BUY	$2.7 - $3.59 $13 - $17	5 Added 2.94%	175 $1,000
Q2 2021 Aug 16, 2021	SELL	$3.21 - $4.06 $3 - $4	-1 Reduced 0.58%	170 $1,000
Q1 2021 May 13, 2021	BUY	$3.7 - $6.42 $632 - $1,097	171 New	171 $1,000

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $72.7M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.